Compare Medtronic PLC (MDT) vs Philip Morris International Inc. (PM) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with a bullish technical signal and strong analyst consensus. Recent financials show robust revenue growth to $40.65B in 2025 and net income of $11.35B, though a Q4 2025 earnings miss and a recent $500M impairment charge highlight near-term pressures. The stock's P/E of 27.17 and P/S of 7.25 reflect premium valuation, supported by a 68% buy rating from analysts and a $194.00 consensus price target.

Outlook remains positive with steady cash flow and dividend payments, but risks include regulatory challenges from rising illicit cigarette trade in Europe and cost pressures. The stock offers stability through high margins and brand strength, yet investors should weigh valuation against earnings volatility and macroeconomic headwinds.